CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

• 主要な著者: Xinyi Huang (著者), Chao Li (著者), Chaopeng Li (著者), Zhenyu Li (著者), Xiaohui Li (著者), Jianwei Liao (著者), Tai Rao (著者), Lulu Chen (著者), Lichen Gao (著者), Dongsheng Ouyang (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Depression disorder is one of the most serious mental illnesses in the world. Escitalopram is the essential first-line medication for depression disorder. It is the substrate of hepatic cytochrome P450 (CYP) enzyme CYP2C19 with high polymorphism. The effect of CYP2C19 on pharmacokinetics and pharmac...